0.375
0.00 (0.00%)
| Previous Close | 0.375 |
| Open | 0.370 |
| Volume | 1,900,115 |
| Avg. Volume (3M) | 1,999,485 |
| Market Cap | 146,035,872 |
| Price / Sales | 1.98 |
| Price / Book | 7.28 |
| 52 Weeks Range | |
| Earnings Date | 26 Feb 2025 - 3 Mar 2025 |
| Diluted EPS (TTM) | -0.200 |
| Total Debt/Equity (MRQ) | 1.00% |
| Current Ratio (MRQ) | 7.22 |
| Operating Cash Flow (TTM) | -65.94 M |
| Levered Free Cash Flow (TTM) | -48.04 M |
| Return on Assets (TTM) | -86.16% |
| Return on Equity (TTM) | -151.39% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (AU) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | PARA BIO FPO [PAR] | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | -2.0 |
| Average | 0.25 |
|
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulphate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 12.31% |
| % Held by Institutions | 15.40% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |